Our signature company is atai Life Sciences, which we have founded ourselves in 2018 and which within just 3 years has raised more than USD 350 million and covers the entire spectrum of new mental health treatments with more than 13 substances in its pipeline. Beyond atai we have a broad portfolio of companies in the mental health & neuroscience field, from depression treatments to new solutions for Alzheimer’s and dementia.